



1645 #39/165
02-2702

Dkt. 41426-D/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

Applicants : Ron S. Israeli, et al.
Serial No. : 08/470,735 Group Art Unit: 1645
Filed : June 6, 1995 Examiner: S. Gucker
For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas
New York, New York 10036
November 2, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

**COPY OF PAPERS
ORIGINALLY FILED**

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e) (2)**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following reference which is listed on the PTO-1449 form attached hereto as **Exhibit A**. A copy of this reference is attached hereto as **Exhibit 1**.

U.S. Patent No. 6,290,956 issued October September 18, 2001
to Bander (Exhibit 1).

In addition, applicants note that the October 9, 2001 Official Gazette indicates that all references to Patent No. 6,290,956 to Neil H. Bander of Chappaqua, N.Y. for TREATMENT AND DIAGNOSIS OF PROSTATE CANCER appearing in the Official Gazette of September 18, 2001 should be deleted since no patent was granted.

In compliance with 37 C.F.R. §1.97(e)(2), no item of information contained in this supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the

RECEIVED

FEB 6 2002

TECH CENTER 1600/2900


Applicants : Ron S. Israeli, et al.
Serial No. : 08/470,735
Filed : June 6, 1995
Page 2

person signing the certification after making reasonable inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to filing this supplemental information disclosure statement.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. §1.97(c)(1), no fee is deemed necessary in connection with the filing of this supplemental information disclosure statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 1-2-01
John P. White
Reg. No. 28,678
Spencer H. Schneider
Reg. No. 45,923

Date

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400